Last Update 02 Feb 26

TWST: Sector Recovery Optimism Will Likely Outrun Synthetic Biology Market Realities

Analysts have lifted their price targets on Twist Bioscience by up to about $10, citing improving sentiment into 2026, recovering end markets, and what they see as multiple potential avenues for growth in the tools and synthetic biology businesses, despite some remaining questions on market size.

Analyst Commentary

Recent research commentary has generally leaned constructive on Twist Bioscience, with several firms lifting their price targets and pointing to tools and synthetic biology as potential growth drivers into 2026. At the same time, some of the research gives a glimpse into where expectations could be getting stretched, especially around how big certain markets can realistically be and how quickly Twist can capture share.

On the more constructive side, one firm raised its price target to $43 from $32 as part of a broader reset across the diagnostic tools group. The firm highlighted what it views as a clearer multi year framework and several possible ways for Twist to add upside to what it sees as already derisked growth assumptions. Another firm lifted its target to $42 from $34, arguing that improving end markets and sector rotation have set up Twist as a possible 2026 tools story, while also flagging healthy procedure and capital spending trends and early recovery signs in China for the broader group.

Even the more cautious research does not dispute that Twist is winning share in certain areas. One firm, which now has a $37 price target compared with $40 previously, pointed to management's push to be, in its words, "commercially violent" as a factor in gaining customers. At the same time, that same research note and other bearish analysts continue to question how large Twist's addressable markets really are, especially in synthetic biology, and how that uncertainty should factor into valuation.

Across these notes, a common thread is that 2026 guidance is a key focus. Bulls see it as a way to firm up multi year expectations. Bearish analysts, however, are watching closely for any sign that current enthusiasm could be running ahead of what the underlying markets and Twist's execution can support.

Bearish Takeaways

Bearish analysts highlight that at least one firm reduced its price target to $37 from $40, which they see as a signal that expectations may already embed a lot of success and leave less room for execution missteps.
Questions around the true size of Twist's market opportunities, especially in synthetic biology, are a core concern for bearish analysts, who worry that current valuations might be built on addressable market estimates that prove too optimistic.
Some bearish analysts are cautious that management's aggressive commercial approach could support near term share gains but might not fully resolve longer term growth risks if end markets or customer budgets do not expand as expected.
Bearish analysts also flag that with multiple firms now positioning Twist as a 2026 tools story, any guidance that falls short of these emerging expectations could compress valuation and refocus attention on execution and capital allocation discipline.

What's in the News

Twist Bioscience launched research grade Plasmid DNA Preps aimed at supporting pharmaceutical and biotech customers in pre clinical studies, focused on nucleic acid therapeutics discovery and development (Key Developments).
The new Plasmid DNA Preps are animal origin free and transfection grade, with options that align to specific preclinical quality requirements such as low or endotoxin free DNA for use in delicate cells (Key Developments).
Twist offers low and endotoxin free transfection grade preps, along with animal origin free options supported by TSE and BSE certificates, targeting customers that require documented quality standards (Key Developments).
Customers can choose target yields from 4 ug to 10 ug per prep so they receive consistent and precise DNA mass across experiments, which is intended to reduce variability and risk in discovery programs (Key Developments).
The company reports that its platform technologies are designed to support cost effective, rapid, precise, high throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of DNA tools for research workflows (Key Developments).

Valuation Changes

Fair Value: Kept unchanged at $33.0, indicating no adjustment to the core valuation anchor in this update.
Discount Rate: Edged down slightly from 7.12% to 7.08%, a small change that modestly increases the weight on future cash flows in the model.
Revenue Growth: Moved up slightly from 16.17% to 16.37%, reflecting a marginally higher assumed growth rate in the forecasting period.
Net Profit Margin: Ticked up from 16.72% to 16.96%, implying a small adjustment to expected profitability on future revenues.
Future P/E: Reduced modestly from 26.70x to 26.17x, suggesting a slightly lower valuation multiple applied to projected earnings.

0 views

Key Takeaways

Intensifying competition and industry consolidation are driving down margins, pressuring Twist Bioscience to increase spending on innovation and commercialization.
Heavy reliance on a few customers heightens revenue volatility, while operational costs and regulatory risks challenge the path to consistent profitability.
Ongoing product innovation, strategic market expansion, and improved margins position Twist Bioscience for robust long-term growth with increasing profitability and diversified revenue streams.

Catalysts

About Twist Bioscience

Manufactures and sells synthetic DNA-based products.What are the underlying business or industry changes driving this perspective?

The increasing commoditization of DNA synthesis and next-generation sequencing services, driven by rapid advancements in AI-driven protein design and DNA manufacturing, threatens to erode Twist Bioscience's technological differentiation, resulting in sustained pricing pressure and contraction of gross margins over the next several years.
Persistent customer concentration risk remains in both the NGS and SynBio businesses, leaving revenues highly exposed to contract delays or the loss of a handful of large pharma or diagnostic accounts. Recent quarter results already show revenue impacts from single-customer order timing and transitions, foreshadowing potential future volatility and impairing predictability of earnings.
Escalating international trade tensions and the risk of tighter global biosecurity or data privacy regulations could disrupt supply chains, drive up input costs, and increase compliance expenditure for Twist, putting downward pressure on net margins while undermining the company's ability to deliver on global revenue growth targets.
While the company is investing heavily in R&D and platform expansion in pursuit of profitability, persistent high operational expenditures without the realization of scalable profit could result in extended negative net margins, particularly if revenue growth decelerates or fails to outpace rising costs amid an increasingly competitive landscape.
Large, well-capitalized competitors and aggressive industry consolidation threaten to intensify customer acquisition costs and force Twist to accelerate reinvestment into both product innovation and commercial infrastructure. This scenario risks diluting operating leverage, suppressing future earnings per share, and potentially stalling the company's path to sustainable profitability.

Twist Bioscience Earnings and Revenue Growth

Twist Bioscience Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Twist Bioscience compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Twist Bioscience's revenue will grow by 15.4% annually over the next 3 years.
The bearish analysts are not forecasting that Twist Bioscience will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Twist Bioscience's profit margin will increase from -23.5% to the average US Biotechs industry of 16.3% in 3 years.
If Twist Bioscience's profit margin were to converge on the industry average, you could expect earnings to reach $90.4 million (and earnings per share of $1.37) by about August 2028, up from $-85.2 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 22.2x on those 2028 earnings, up from -19.9x today. This future PE is greater than the current PE for the US Biotechs industry at 15.6x.
Analysts expect the number of shares outstanding to grow by 3.03% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Twist Bioscience Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The company reported significant year-over-year revenue growth across all major segments, including SynBio (7% growth) and NGS (27% growth), as well as expansion into new customer bases and markets, which points to underlying revenue strength and ongoing customer demand.
Gross margin has improved dramatically, rising from 31% to over 53% in two years, with management guiding for continued gross margin expansion, supporting future improvements in net margins and overall profitability.
Twist Bioscience's ongoing product innovation-including internally manufactured primers, new SynBio offerings, and differentiated high-throughput solutions-positions the firm to benefit from long-term secular trends in synthetic biology, which could drive sustained growth in top-line revenue and earnings.
The company is seeing strong adoption within the clinical segment of NGS and emerging growth in minimal residual disease (MRD), with management expecting further commercial launches in 2026 and 2027 that could lead to sequential growth and recurring revenue streams, bolstering earnings stability.
Management highlighted successful customer diversification in both industrial and academic markets, combined with disciplined OpEx management and a clear commitment to reaching adjusted EBITDA breakeven, indicating a strong strategic focus on improving net profits and ensuring sustained financial health.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Twist Bioscience is $25.0, which represents the lowest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of Twist Bioscience's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $25.0.
In order for you to agree with the bearish analysts, you'd need to believe that by 2028, revenues will be $556.1 million, earnings will come to $90.4 million, and it would be trading on a PE ratio of 22.2x, assuming you use a discount rate of 6.8%.
Given the current share price of $28.12, the bearish analyst price target of $25.0 is 12.5% lower. Despite analysts expecting the underlying buisness to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Twist Bioscience?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

DNA Synthesis Commoditization And Trade Tensions Will Erode Margins